We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate

Product News   Feb 24, 2011

 
Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate
FURTHER INFORMATION
 
 
 

Related Product News

Advancing the Possibility of Personalized Neoantigen Cancer Vaccines

Product News

NEC and VAXIMM, a biotech company focused on developing oral T-cell immunotherapies, have announced a clinical trial collaboration to develop novel personalized neoantigen cancer vaccines.

READ MORE

Advances in Bavarian Nordic’s Cancer Immunotherapy Platform

Product News

A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform has been published in Nature Communications.

READ MORE

Combined Whole Transcriptome and Protein Analysis Solution for HD Immunology

Product News

BD has launched a combined whole transcriptome and protein analysis solution for HD immunology.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE